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PKCThe novel PKCθ isoform is highly expressed in T-cells, brain and skeletal muscle and originally thought to have
a restricted distribution. It has been extensively studied in T-cells and shown to be important for apoptosis,
T-cell activation and proliferation. Recent studies showed its presence in other tissues and importance in
insulin signaling, lung surfactant secretion, intestinal barrier permeability, platelet and mast-cell functions.
However, little information is available for PKCθ activation by gastrointestinal (GI) hormones/neurotransmitters
andgrowth factors. In thepresent studyweused rat pancreatic acinar cells to explore their ability to activate PKCθ
and the possible interactions with important cellular mediators of their actions. Particular attention was paid to
cholecystokinin (CCK), a physiological regulator of pancreatic function and important in pathological processes
affecting acinar function, like pancreatitis. PKCθ-protein/mRNA was present in the pancreatic acini, and T538-
PKCθ phosphorylation/activationwas stimulated only by hormones/neurotransmitters activating phospholipase
C. PKCθ was activated in time- and dose-related manner by CCK, mediated 30% by high-afﬁnity CCKA-receptor
activation. CCK stimulated PKCθ translocation from cytosol to membrane. PKCθ inhibition (by pseudostrate-
inhibitor or dominant negative) inhibited CCK- and TPA-stimulation of PKD, Src, RafC, PYK2, p125FAK and IKKα/β,
but not basal/stimulatedenzymesecretion.AlsoCCK-andTPA-inducedPKCθ activationproducedan increment in
PKCθ's direct association with AKT, RafA, RafC and Lyn. These results show for the ﬁrst time the PKCθ presence in
pancreatic acinar cells, its activation by some GI hormones/neurotransmitters and involvement in important cell
signaling pathways mediating physiological responses (enzyme secretion, proliferation, apoptosis, cytokine
expression, and pathological responses like pancreatitis and cancer growth).f cholecystokinin; TPA, 12-O-
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Protein kinase C θ (PKCθ) belongs to the threonine/serine kinase
superfamily PKC [1]. In mammals this superfamily is comprised of 12
isoformsdivided in3groupsdependingon their activation requirements:
conventional PKC isoforms (α, βI, βII and γ), which activation depends
onDAGandCa2+; novel (δ, ε,η and θ),whose activationdependsonDAG
but not Ca2+ and atypical (λ/ι, μ and ζ), whose activation is independent
from both DAG and Ca2+ [1]. Once activated by phosphorylation and
cofactor binding [2], PKCs stimulate serine/threonine phosphorylation of
many cellular proteins including other kinases, cytoskeletal proteins,
structural proteins, enzymes, adapter proteins and receptors, and their
activation hasmultiple effects in both normal and pathological processes
including differentiation, proliferation, apoptosis, cell death, secretion,
adhesion and cell migration [3].
The novel PKCθ isoform, which is the most recently described [4],
was originally thought to have a restrictive distribution with high
expression in T-cells [4], brain [4] and skeletal muscle [4]. Its activation
and effect on various cellular processes have been primarily studied in
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show that PKCθ is more widely distributed than originally described [4]
and it has been detected in a number of other tissues such as in testis [4],
intestinal epithelial cells [6] and mast cells [7]; and in several human
tumor and tumor cell lines [such as human gastrointestinal stromal
tumor [8], human colorectal cancer [9] and gastric cancer cells KATO-III
[10]].
Studies demonstrate that PKCθ activation plays an important
function in various tissues including T cell antigen receptor (TCR)
activation, proliferation, apoptosis [5], insulin secretion [11], insulin
signaling in muscle [12], barrier permeability in intestinal epithelium
[6], thrombus formation in platelets [13] and mast cell activation [7].
However, there is little information on the activation of PKCθ by
gastrointestinal (GI) hormones/neurotransmitters and growth factors.
Pancreatic acinar cells are an excellent model system to study
kinase activation by GI hormones/neurotransmitters and growth
factors because many GI hormones/neurotransmitters and growth
factors can alter pancreatic acinar function and signaling cascades
including phospholipases (A, C, D), adenylate cyclase, tyrosine kinases
and other serine/threonine kinases [14–19]. In pancreatic acinar cells
from normals or animals with pancreatic disorders (pancreatitis,
pancreatic cancer), PKC activation, including conventional and other
novel PKCs (PKCδ and PKCε), has been implicated in several processes.
These include enzyme secretion, activation of proteases, inﬂammatory
responses, growth and apoptotic pathways stimulated by various
pancreatic hormones/neurotransmitters or growth factors, as well as
other stimulants [20–24]. At present, it is unclear whether PKCθ is
present in pancreatic acinar cells, whether any pancreatic neurotrans-
mitter/hormones or growth factors can activate it or whether it
participates in any of signaling cascades mediating either the
physiological or pathological processes caused by pancreatic neuro-
transmitter/hormones or growth factor stimulation of pancreatic acinar
cells.
The purpose of the present study was to address these issues and
to determine whether PKCθ is present in pancreatic acinar cells, if
gastrointestinal hormones/neurotransmitters can activate this novel
protein kinase, PKCθ, and if so, to provide insights into the possible
mechanisms of its interactions with various known important cellular
mediators of the actions of these pancreatic stimulants. Particular
attention was paid to the hormone/neurotransmitter, cholecystokinin
(CCK), because it is not only a physiological regulator of pancreatic
acinar cell function, it is also important in a number of important
pathological processes affecting acinar cell function, such as pancre-
atitis [23,25,26].
2. Materials and methods
2.1. Materials
Male Sprague–Dawley rats (150–250 g) were obtained from
the Small Animals Section, Veterinary Resources Branch, National
Institutes of Health (NIH), Bethesda, MD. Rabbit anti-phospho-protein
kinase C θ (PKCθ) pT538, rabbit anti-PKCθ, rabbit anti-phospho-Src
family (Y416), mouse monoclonal anti-phospho p44/42 mitogen-
activated protein kinase (MAPK) (T202/Y204) (E10), rabbit anti-Akt,
rabbit anti-RafA, rabbit monoclonal anti-RafB (55C6), rabbit anti-RafC,
rabbit anti-protein kinaseD (PKD), rabbit anti-protein kinase δ (PKCδ),
rabbit anti-14-3-3-γ, rabbit monoclonal anti-Bcl-10 (C78F1), rabbit
anti-Mucosa-associated lymphoid tissue translocation gene 1 (MALT-1),
rabbit anti-c-Cbl, rabbit anti-phospho Akt (T308), rabbit anti-phospho-
IκB kinase (IKK) IKKα (Ser180)/IKKβ (Ser181), rabbit monoclonal anti-
phospho Raf C (56A6), rabbit phospho-PKD (Ser744/748), rabbit
phospho-FAK (Tyr397), rabbit phospho-Pyk2 (Tyr402), rabbit phospho-
PKCδ (Tyr311), rabbit anti-α/β tubulin antibodies and nonfat dry
milk were purchased from Cell Signaling Technology, Inc. (Beverly,
MA). Mouse monoclonal anti-PKCθ (E-7) antibody, mouse monoclonalanti-Lyn (H-7), mouse anti-pan Src, bovine anti-goat horseradish
peroxidase (HRP)-conjugate and anti-rabbit-HRP-conjugate antibodies
were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse
monoclonal anti-PKCθ (clone 27) was purchased from BD Biosciences
(San Jose, CA). Mouse monoclonal anti-cadherin (36/E) antibody was
from BD Transduction laboratories (Lexington, KY). Mouse monoclonal
anti-calpain (15C10) antibody was from Biosource International,
Inc. (Camarillo, CA). Rabbit anti-phosphatidylinositol-3-kinase p85
(PI3K) was purchased from Upstate Biotechnology (Lake Placid, NY).
Tris/HCl pH 8.0 and 7.5 were from Mediatech, Inc. (Herndon, VA).
2-mercaptoethanol, protein assay solution, sodium lauryl sulfate (SDS)
and Tris/Glycine/SDS (10×) were from Bio-Rad Laboratories (Hercules,
CA). MgCl2, CaCl2, Tris/HCl 1 M pH 7.5 and Tris/Glycine buffer (10×)
were fromQuality Biological, Inc. (Gaithersburg,MD).Minimal essential
media (MEM) vitamin solution, Dulbecco's Modiﬁed Eagle Medium
(DMEM), Waymouth's medium, basal medium Eagle (BME) amino
acids 100×, Dulbecco's phosphate buffered saline (DPBS), glutamine
(200 mM), Tris–Glycine gels, L-glutamine, fetal bovine serum (FBS),
0.05% trypsine/EDTA solution, penicillin–streptomycin, Alexa594, Alexa
488-conjugated anti-rabbit secondary antibodies and glycerol were
from Invitrogen (Carlsbad, CA). COOH-terminal octapeptide of chole-
cystokinin (CCK), hepatocyte growth factor (HGF), bombesin, insulin-
like growth factor 1 (IGF-1), basic ﬁbroblast growth factor (bFGF),
vasoactive intestinal peptide (VIP), endothelin and secretin were from
Bachem Bioscience Inc. (King of Prussia, PA). CCK-JMV-180 (CCK-JMV)
was obtained from Research Plus Inc., Bayonne, NJ. Epidermal growth
factor (EGF), thapsigargin, platelet-derivedgrowth factor (PDGF), vascular
endothelial growth factor (VEGF), deoxycholic acid, protein kinase C
isoenzyme sample kit andmyristolated PKCθ pseudosubstrate were from
Calbiochem (La Jolla, CA). Carbachol, insulin, transforming growth factor
beta (TGFβ), dimethyl sulfoxide (DMSO), 12-O-tetradecanoylphobol-13-
acetate (TPA), 8-bromoadenosine 3′5′ cyclic monophosphate sodium
(8-Bromo-cAMP), L-glutamic acid, glucose, fumaric acid, pyruvic acid,
trypsin inhibitor, HEPES, TWEEN® 20, Triton X-100, phenylmetha-
nesulfonylﬂuoride (PMSF), ethylenediaminetetraacetic acid (EDTA),
ethylene glycol tetraacetic acid (EGTA), sucrose, sodium-orthovanadate,
sodiumazide, Nonidet P40, sodiumpyrophosphate,β-glycerophosphate,
sodium ﬂuoride, dithiothreitol, AEBSF, MOPS (3-(N-morpholino)propa-
nesulfonic acid), methanol and CeLytic™MCell Lysis Reagent were from
Sigma-Aldrich, Inc. (St. Louis, MO). Albumin standard, Protein G agarose
beads and Super Signal West (Pico, Dura) chemiluminescent substrate
were from Pierce (Rockford, IL). Protease inhibitor tablets, pepstatin,
leupeptine and aprotine were from Roche (Basel, Switzerland). Puriﬁed
collagenase (type CLSPA) was from Worthington Biochemicals (Free-
hold, NJ). Nitrocellulose membranes were from Schleicher and Schuell
Bioscience, Inc. (Keene, NH). Biocoat collagen I Cellware 60 mm dishes
were from Becton Dickinsen Labware (Bedford, MA). Albumin bovine
fraction V was from MP Biomedical (Solon, OH). NaCl, KCl, acetone,
phosphoric acid and NaH2PO4 were from Mallinckrodt (Paris, KY). HEK
293 cells were from ATCC (Manassas, VA). Dominant negative PKCθ
adenovirus, Quick Titer™ Adenovirus Quantiﬁcation Kit and ViraBind™
Adenovirus Puriﬁcation Kit were from Cell Biolabs, Inc. (San Diego, CA).
Ad-CMV-Null was from Vector Biolabs (Philadelphia, PA). RNA PCR Kit,
DNA-polymerase (AmplitaqGold), 10×PCRbuffer anddeoxynucleotides
were from Applied Biosystems (Foster City, CA). L-364,718 (3S(−)-N-
(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-yl-
1H-indole-2-carboxamide) and L-365,260 (3R(+)-N-(2,3-dihydro-1-
methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N′-(3-
methylphenyl)urea) were from Merck, Sharp and Dohme (West
Point, PA). YM022 ((R)-1-[2,3-dihydro-1-(2′-methyl-phenacyl)-2-
oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)
urea) and SR27897 (1-[[2-(4-(2-chlorophenyl)-thiazol-2-yl)amino-
carbonyl] indolyl]acetic acid were from Tocris Bioscience (Ellisville,
MO). Phadebas reagent was fromMagle Life Science (Lund, Sweden).
PKC Assay Kit and Histone H1 were from Millipore (Temecula, CA).
[γ-32P]ATP (3000 Ci/mmol) was from Perkin Elmer (Waltham, MA).
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2.2.1. Tissue preparation
Pancreatic acini were obtained by collagenase digestion as previously
described [17]. Standard incubation solution contained 25.5 mM HEPES
(pH 7.45), 98 mM NaCl, 6 mM KCl, 2.5 mM NaH2PO4, 5 mM sodium
pyruvate, 5 mM sodium glutamate, 5 mM sodium fumarate, 11.5 mM
glucose, 0.5 mMCaCl2, 1 mMMgCl2, 1 mMglutamine, 1% (w/v) albumin,
0.01% (w/v) trypsin inhibitor, 1% (v/v) vitamin mixture and 1% (v/v)
amino acid mixture.
2.2.2. Acini stimulation
After collagenase digestion, dispersed acini were pre-incubated in
standard incubation solution for 2 h at 37 °C with or without inhibitors
as described previously [17,27]. Protein concentration was measured
using theBio-Radprotein assay reagent. Equal amounts of sampleswere
analyzed by SDS-PAGE and Western blotting.
2.2.3. cDNA preparation
Random hexamer-primed ﬁrst strand cDNA was obtained with RT
(RNA PCR Kit) from mRNA from rat muscle, pancreas and brain
(Stratagene, Clontech and Bio-chain, respectively).
2.2.3.1. PCR. Primers for PKCθ was selected through analysis of the rat
PKCθ mRNA sequence (GenBank accession no AB020614.1). The sense
and antisense sequences of the PKCθ primer were as follows: sense,
5′-TAGAAAGGGAGGCCAAGGAT-3′ (nucleotides 236–256); and anti-
sense, 5′-CTGAAGGGTGGGTCAATCTC-3′ (nucleotides 367–386) giving
a PCR product size of 151 bp. The presence of the PKCθ mRNA was
determined in cDNA samples from ratmuscle, pancreas and brain, using
genomic DNA as negative control. The PCR was conducted with
40 cycles, which were within the linear ampliﬁcation range. The PCR
began with a cycle of 94 °C for 10 min, followed by 40 cycles of 94 °C
for 40 s (denaturing), 58 °C for 40 s (annealing), and 72 °C for 40 s
(elongation). A ﬁnal extension period of 94 °C for 5 min concluded the
ampliﬁcation. PCR products were size-fractionated on agarose gels,
stained with ethidium bromide and visualized under UV light.
2.2.4. Western blotting/immunoprecipitation
Western blotting and immunoprecipitation were performed as
described previously [19]. The intensity of the protein bands was
measured using Kodak ID Image Analysis, which were assessed in the
linear detection range.When re-probingwas necessarymembraneswere
incubated in Stripping buffer (Pierce, Rockford, IL) for 30 min at room
temperature, washed twice for 10 min in washing buffer, blocked for 1 h
in blocking buffer at room temperature and re-probed as described above.
2.2.5. Translocation
Translocation studies were performed as described previously [16].
Brieﬂy, after stimulation, acini were resuspended in membrane lysis
buffer (50 mMTris/HCl pH 7.5, 150 mMNaCl, 0.1% sodium azide, 1 mM
EGTA, 0.4 mM EDTA, 0.2 mM sodium orthovanadate, 1 mM PMSF, and
one protease inhibitor tablet per 10 ml). After homogenization, lysates
were cleared by centrifugation. The supernatant (cytosol and mem-
brane fraction) was centrifuged for 30 min at 4 °C and 60,000×g. The
pellet containing the membrane fraction was washed twice in
membrane lysis buffer, resuspended in lysis buffer (50 mM Tris/HCl
pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% sodium
azide, 1 mMEGTA, 0.4 mMEDTA, 0.2 mMsodiumorthovanadate, 1 mM
PMSF, and one protease inhibitor tablet per 10 ml), sonicated and then
centrifuged at 10,000×g for 15 min at 4 °C. Equal amounts of protein
were subjected to SDS-PAGE and analyzed by Western blotting.
2.2.6. Immunocytochemistry and immunoﬂuorescence imaging
After treating isolated pancreatic acini with orwithout stimulants as
indicated, cells were ﬁxed, transferred to glass slides and blocked aspreviously described [28], then slides were incubated with a rabbit
anti-pT538 PKCθ antibody and a mouse anti-cadherin antibody at a
dilution of 1:500 overnight at 4 °C. Reactivity was demonstrated by
incubation with an Alexa 488-conjugated anti-rabbit or with an Alexa
555-conjugated anti-mouse secondary antibody, respectively, at a
dilution of 1:500 for 2 h RT. Negative controls consisted of replacement
of primary antibody with an isotype-matched control. Slides were
analyzed as previously reported [28].
2.2.7. Amylase release
Amylase release from isolated pancreatic acinar cells was measured
as previously described [29,30]. Amylase activity was determined with
the Phadebas reagent and expressed as % of total cellular amylase
released into the extracellular medium during the incubation time.
2.2.8. Co-immunoprecipitation (Co-IP)
Co-IP studies were performed as previously described [14]. Brieﬂy,
cells were lysated with CelLytic Buffer (CelLytic™M Cell Lysis Reagent
0.2 mM sodiumorthovanadate, 1 mMPMSF, and one protease inhibitor
tablet per 10 ml), and lysates (750 μg/ml) were incubated with 4 μg of
the required antibody and with 25 μl of protein G-agarose at 4 °C,
overnight. The immunoprecipitates were washed with phosphate-
buffered saline and analyzed by SDS-PAGE and Western blotting.
2.2.9. Virus infection and culture acini
Pancreatic acini were isolated as described above, infected with
either Ad-CMV-Null (empty adenovirus, as infection control) or
dominant negative PKCθ adenovirus at 1×109 VP/ml concentration, as
described previously [18]. After 6 h, stimulants were added and cells
lysed as described above).
2.2.10. PKCθ kinase activation assay
PKCθ kinase activation was measured as previously described [14].
Brieﬂy, after isolation and incubation with 10 nM CCK or 1 μM TPA, 1
and 2.5 min, respectively, pancreatic acinar cellswere lysated, PKCθwas
immunoprecipitated with 4 μg BD PKCθ antibody and 25 μl Protein G
agarose beads overnight, 4 °C Kinase assays were performed on the
PKCθ immunoprecipitates in two different ways: one using the PKC
substrate peptide (QKRPSQRSKYL) provided by the PKC kinase assay
kit fromMillipore (Temecula, CA), following the directions provided by
the manufacturer; and the other using Histone H1 (1 μg/sample). The
substrate peptide was spotted on to p81 ﬁlter paper and processed
according to themanufacturer's instructions.When PKCθ kinase activity
was measure as increments in the 32P-phosphorylation of the protein
histone H1, the reaction was terminated by the addition of 15 μl of
loading buffer and 5 min at 95 °C, samples were subjected to SDS-PAGE
electrophoresis, gels dried and analyzed in a phosphor imager
(InstantImager, Packard Instruments Co.
2.2.11. Statistical analysis
All experiments were performed at least 3 times. Data are
presented as mean±SEM and were analyzed using the Student's
t-test for paired data using the software StatView (SAS Institute,
Casy, NC). p valuesb0.05 were considered signiﬁcant. Curve ﬁtting,
EC50 and tmax were determined using the GraphPad 5.0 software.
3. Results
3.1. Presence of PKCθ mRNA and protein in pancreas
It is well established that four PKC isoforms (α, δ, ε, ζ) are expressed
in rat pancreatic acini [14,24], but also there are contradictory data
regarding the presence in this tissue of the novel isoform PKCθ
[24,29,31,32]. In order to clarify this point, both studies of the presence
in rat pancreas of PKCθ mRNA and PKCθ protein were determined
(Fig. 1). PCRusing speciﬁc primers for PKCθmRNAwith cDNAsobtained
Fig. 1. Presence of PKCθmRNA and protein in pancreas. Panel A: PCR results using PKCθ
speciﬁc primers and cDNA from rat muscle and rat brain, known to contain PKCθ, and
from rat pancreas. Panel B: Presence of the protein PKCθ in isolated pancreatic acini.
Lysates from pancreatic acini were run in parallel with different human recombinant
PKC isoforms (α, δ, ε, θ and ζ) and detected by Western blotting (WB) with a speciﬁc
anti-PKCθ antibody (Cell signaling). Panel C: Speciﬁcity of PKCθ antibodies was
examined by immunoprecipitation (IP) of the PKC isoforms (α, δ, ε, θ and ζ) from
pancreatic acini lysate with a speciﬁc anti-PKCθ anti-mouse antibody (BD Biosciences)
and detection with a speciﬁc anti-PKCθ anti-rabbit antibody (Cell Signaling). A single
band was obtained just in the case of PKCθ isoform, showing the speciﬁcity of the
antibodies used.
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pancreas was performed, and it resulted in a single band of 151 bp in
all cases (Fig. 1, Panel A, Rows 1–3). To determine whether the PKCθ
protein is present in pancreatic acini, a Western blot was perform
with different human recombinant PKC isoforms running in parallel
with lysate obtained from rat pancreas acini (Fig. 1, Panel B).
Immunodetected with a PKCθ total antibody (Cell Signaling),
resulting in a single band of 80 kDa in the pancreatic acinar lysate
and only with recombinant human PKCθ (Fig. 1, Panel B, Rows 1 and
4), showing the presence of PKCθ protein in rat pancreatic acini. The
speciﬁcity of the PKCθ antibody used was assessed by immunopre-
cipitation of the known isoforms present in the lysates of the pancreas
acini (α, δ, ε, ζ) with PKC speciﬁc antibodies as well as with a PKCθ
antibody (BD Bioscience), with subsequent analysis by Western blot,
using a different total PKCθ antibody (Cell Signaling) for the immuno-
detection. Only one band of 80 kDa was detected in the lane
corresponding to the immunoprecipitationwith the total PKCθ antibody
(Fig. 1, Panel C, Row 5), demonstrating the speciﬁcity of the antibodies
for PKCθ.3.2. Ability of various pancreatic secretagogues and pancreatic growth
factors to stimulate PKCθ phosphorylation (pT538) in rat pancreatic acini
In order to establish whether PKCθ is not only expressed but also
activated by known pancreatic secretagogues or growth factors [15], rat
pancreatic acini were incubated in the absence and presence of several
gastrointestinal hormones (CCK, carbachol, bombesin, secretin, VIP)
known to activate pancreatic acinar cells and cause enzyme secretion
[15]. The pancreatic secretagogues that activate phospholipase C (CCK,
carbachol and bombesin) stimulated a signiﬁcant increase in the PKCθ
phosphorylation in threonine 538 (pT538) (Fig. 2, Panel A, Rows 2–4).
Neither of the gastrointestinal hormones (VIP and secretin) that cause
an increase in the cAMP,nor the cAMPanalog, 8-Bromo-cAMPwere able
to increase thephosphorylation of PKCθ T538 (Fig. 2, Panel A, Rows 5–8).
As a measurement of PKCθ activity the phosphorylation of T538 of
PKCθwas assessed because it is known that an increase in the threonine
538 phosphorylation of PKCθ is directly related to the activation of this
enzyme [33].
None of the known pancreatic growth factors (insulin, EGF, PDGF,
VEGF, bFGF, IGF, TGFβ and HGF) [15] were able to activate PKCθ and
stimulate threonine 538 phosphorylation of PKCθ (Fig. 2, Panel B,
Rows 3–10). This lack of stimulationwas not due to the inability of the
growth factors to activate acinar cells because each stimulated pS473
Akt phosphorylation (data not shown).
In order to determine if any of the CCK stimulating effect on pT538
PKCθ phosphorylation was caused by the presence/activation of CCKA
or CCKB receptors in the pancreatic acinar cell, isolated acinar cells
were ﬁrst incubated with either CCK, gastrin, or a known CCKA
receptor agonist (A71378) [34] (Fig. 2, Panel C, Lanes 1–4). Gastrin did
not produce any increase in pT538 PKCθ phosphorylation, and that the
CCK activation of PKCθ was mimicked by the incubation of the cells
with the CCKA receptor agonist. Moreover, when the acinar cells were
incubated with CCK and two different CCKA receptor antagonists
[L364,718 or SR27897] [30,35] the increment in PKCθ phosphorylation
observed in the sole presence of CCK was completely inhibited, but
not in the presence of CCKB receptor antagonists [L365,260 or YM022]
[30,36] (Fig. 2, Panel C, Lanes 5–10). These results demonstrate that
the observed effect of CCK in PKCθ phosphorylation is only due to the
activation of the CCKA receptors.
3.3. Dose–response effect of CCK and CCK-JMV on PKCθ T538
phosphorylation in rat pancreatic acini
As CCK has an important role in both the physiology and
pathophysiology of the pancreas [15,37], we focused our study in the
activation of PKCθ exerted by this hormone in rat pancreatic acini.
Increasing concentrations of CCK produced a biphasic increase in T538
phosphorylation of PKCθ with concentrations from 0.1 nM to 10 nM
causing increasing stimulation, and then concentrations from 100 to
1000 nM CCK causing less stimulation (Fig. 3, Panel A). The maximal
stimulation occurred with 10 nM CCK (239±25% of control=100±
10% of maximal response) and CCK's half-maximal effect (EC50)
occurred with 0.174±0.008 nM (Fig. 3, Panel A). The CCKA receptor in
pancreatic acini can exist in two different activation states, a low and a
high-afﬁnity state, and the activation of the different states activates
different cell signaling cascades [18,26,38–40]. Inorder to determine the
contribution of each activation receptor state to the activation of PKCθ
by CCK, pancreatic acini were incubated in the presence of increasing
concentrations of CCK-JMV, known to be an agonist of the CCKA high
afﬁnity state and an antagonist of the low afﬁnity CCKA receptor state in
rat pancreatic acini [18,19]. CCK-JMV stimulated threonine 538
phosphorylation of PKCθ in a monophasic manner with concentra-
tions from 10 nM to 1000 nM (Fig. 3) with an EC50 of 1.262±
0.033 nM (Fig. 3, Panel A), and therefore was 7-times less potent than
CCK. CCK-JMV caused 32% of the maximal stimulation of T538 PKCθ
phosphorylation caused by CCK (Fig. 3, Panel A). These results
Fig. 2. Ability of various pancreatic secretagogues and growth factors to stimulate PKCθ
phosphorylation (pT538) in rat pancreatic acini. Panel A: Isolated pancreatic acini were
incubated in the absence or presence of different pancreatic secretagogues for 5 min,
and then lysed.Western blots were analyzed using anti-pT538 PKCθ and anti-total PKCθ
(PKCθ), as loading control. Top: Results of a representative blot of 5 independent
experiments are shown. Bottom: Means±S.E. of 5 independent experiments. Results are
expressed as % of control. *pb0.05 compared to the control group. Panel B: Isolated
pancreatic acini were incubated in the absence or presence of different growth factors
for 5 min and HGF for 10 min, and then lysed. Western blots were analyzed using anti-
pT538 PKCθ and anti-total PKCθ (as loading control). Results of a representative blot of
4 independent experiments are shown. *Signiﬁcantlygreater thancontrol.Panel C: Isolated
pancreatic acini were incubated in the absence or presence of CCK, gastrin or A71378 for
1 min, orpreincubated for 5 min in thepresenceof L364,718, YM022, L365,260or SR27897
and then in the additional presence of CCK 10 nM for 1 min, and then lysed.Western blots
were analyzed using anti-pT538 PKCθ and anti-total PKCθ (as loading control).
Fig. 3. Dose–response effect of CCK and CCK-JMV on PKCθ phosphorylation in rat
pancreas acini. Panel A: Isolated pancreatic acini were incubated in the absence or
presence of CCK and CCK-JMV for 1 min, lysed and subjected to Western blotting as
described in Fig. legend 2. Top: Results of a representative blot of 4–5 experiments is
shown. Bottom: Means±S.E. of 4–5 independent experiments, with CCK or CCK-JMV,
respectively. Results are expressed as % of maximal stimulation caused by CCK. *pb0.05
compared to the control with no additions. Panel B: Isolated pancreatic acini were
incubated in the absence or presence of CCK or TPA for 2.5 min, and then lysed. PKCθ
was immunoprecipitated from equal amount of protein (1 mg/ml) and subjected to
kinase activity measurement, as outlined in the Materials and methods. This result is a
representative experiment of 5 others.
Table 1
Effect of CCK and TPA on PKCθ kinase activity.
Stimulant % Kinase Activity
Substrate peptide Histone H1
None 100±1 100±2
CCK (10 nM) 139±4⁎⁎ 142±4⁎⁎
TPA (1 μM) 235±22⁎⁎ 173±30⁎
PKCθ kinase activity is expressed as the percentage of phosphorylation of either a
substrate peptide or Histone H1 protein, as outlined in Materials and methods. Results
are expressed as means±S.E. of 5 independent experiments.
⁎ pb0.0001.
⁎⁎ pb0.005 vs control.
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mediated 30% by the high afﬁnity state CCKA receptor and 70% by
activation of the low afﬁnity CCKA receptor state. As a CCK
concentration of 10 nM produces the maximal stimulation of PKCθ
phosphorylation, it was selected for the rest of the study.
To further demonstrate that CCKwas activating PKCθ, we studied its
ability to stimulate and increase in PKCθ kinase activity (Table 1, Fig. 3,
Panel B). Both CCK and TPA produced a signiﬁcant increment in the
phosphorylation of the Histone H1 protein (Fig. 3, Panel B) and PKC
substrate peptide (Table 1) which was assessed after performing PKCθimmunoprecipitation from pancreatic acinar cells, previously stimulat-
ed with CCK or TPA (Fig. 3, Panel B).
3.4. Time course of CCK stimulation of PKCθ T538 phosphorylation in rat
pancreatic acini
StimulationofpT538 threoninephosphorylationbyCCKwas rapid and
the time course was biphasic (Fig. 4). Speciﬁcally, CCK stimulated a rapid
initial increase reaching amaximumwithin 1 min (tmax: 0.78±0.08 min)
(maximum: 197±19% of control). Subsequently, the magnitude of
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themaximal but was greater than the basal level for 30 min (145±11%
of control) (Fig. 4).
Because phospholipase C (PLC) stimulating pancreatic hormones,
which subsequently activate PKC, stimulated PKCθ T538 phosphoryla-
tion, the ability of TPA, a known PKC activator, to stimulate PKCθ T538
phosphorylation at different times, was also studied (Fig. 4). TPA
produced, as in the case of CCK, a rapid (1 min) and signiﬁcant increase
(188±13% of control) in PKCθ pT538 phosphorylation (Fig. 4). This
increase was maintained for 5 min, and then the stimulation slowly
decreased over a 30 min period but still remained signiﬁcantly above
the control level (30 min, 171±23%of control).WithTPA, the tmax value
(1.60±0.06 min) was longer than that seen with CCK stimulation.Fig. 5. Ability of CCK and TPA to stimulate translocation of PKCθ to the cell membranes
in rat pancreatic acinar cells. Isolated acini were incubated with or without CCK or TPA
for 1 or 5 min, respectively. Samples were processed as described in Materials and
methods to obtain subcellular fractions, and then subjected to Western blotting. Panel
A: Results from one experiment representative of 5 separate experiments. In the upper
panel, membranes were analyzed using anti-PKCθ antibody. Lower 2 panels: To assess3.5. Ability of CCK and TPA to stimulate translocation of PKCθ to the cell
membranes in rat pancreatic acinar cells
Because PKCθ translocation to the plasma membranes as well as its
pT538 phosphorylation are needed for activation [33,41] we examined
the ability of CCK and TPA to cause translocation of total PKCθ. CCK or
TPA produced a signiﬁcant increment in the membrane associated
PKCθ after 1 min or 5 min incubation, 216±34 and 189±59%of control
pb0.05, respectively (Fig. 5, Panel A (Lanes 1–3) and Panel B). These
incubation times were chosen because this is when both stimulants
exerted their maximum effects on PKCθ phosphorylation (Fig. 4). To
conﬁrm that the separation of the cytosol and membrane fractions
was adequate, equal protein amounts of each fraction were subjected
to Western blot and immunodetection was performed either with
E-cadherin (membrane fraction) or calpain (cytosol marker) antibody
(Fig. 5, Panel A). This immunodetection also showed equal loading in
each experiment condition and good separation of the cytosol and
membrane fractions (Fig. 5, Panel A).
We also studied the translocation of PKCθ to the membrane after
stimulation with CCK or TPA by immunoﬂuorescense-cytochemistry,Fig. 4. Time course of CCK and TPA stimulation of PKCθ T538 phosphorylation in rat
pancreatic acini. Isolated pancreatic acini were incubated in the absence or presence of
CCK or TPA for the indicated times, lysed and subjected toWestern blotting as described
in Fig. legend 2. Top: Results of a representative blot of 5 independent experiments are
shown. Bottom: Means±S.E. of 5 independent experiments. Results are expressed as %
of control. *pb0.05 compared to the control value (i.e. 0 time).
the effectiveness of subcellular fractionation, the cytosol and membrane fractions were
analyzed using anti-calpain antibody, a marker for the cytosol fraction, and anti-E-
Cadherin Ab, a marker for the membrane fraction. Panel B shows the mean values±S.E.
of 5 independent experiments. Results are expressed as % of control. *pb0.05 compared
to the control group.and we observed that in the absence of CCK or TPA, PKCθ was
homogenously distributed through the cytoplasm (Fig. 6, Panel A).
After TPA or CCK treatment, the phosphoT538 PKCθ was increased in
the membrane in both cases (Panels B and C, Fig. 6, respectively), with
the increase caused by TPA more prominent. This results were similar
to those obtain by the membrane fractionating approach (Fig. 5).
3.6. Ability of CCK and TPA to stimulate the association of PKCθ with
various cellular proteins in rat pancreatic acinar cells
PKCθ is reported to interact with a number of other important
cellular signaling proteins in different cell types including Src [41], PKD
[42], Raf [42], CARMA and IKK [43], Cbl [44], 14-3-3 [45], Blc-10 [46],
MALT-1 [47] and Akt [12], kinases known to be particularly important
in regulating growth and apoptosis. In order to determine the possible
interaction of PKCθ with these proteins in the pancreatic acini, we
studied the ability of CCK or TPA to stimulate a direct interaction of PKCθ
with these proteins by performing co-immunoprecipitation (Co-IP)
studies (Fig. 7). We ﬁrst tested 2 different PKCθ antibody's abilities to
immunoprecipitate PKCθ, one that recognized the N terminal sequence
of PKCθ (BD Bioscience) and another that recognizes the C terminal
sequence of PKCθ (Santa Cruz: SC) (Fig. 7, Panel A). We observed that
both PKCθ antibodieswere able to immunoprecipitate the PKCθ isoform
fromhuman recombinant PKCθprotein solution and from rat pancreatic
acini incubated in the absence or presence of CCK (10 nM) and TPA
(1 μM), respectively. We next investigated the Co-IP of PKCθ and the
Fig. 6. PKCθ immunoﬂuorescense-cytochemistry in rat pancreatic acini with and
without TPA or CCK treatment. Pancreatic acini were incubated with no additions, TPA
(1 μM) or CCK (10 nM) for 10 min. After stimulation cells were washed, ﬁxed,
permeabilized and transferred onto poly-l-lysine coated glass slides by cytocentrifuga-
tion as described in Materials and methods. Cells were then labeled using polyclonal
rabbit anti-pT538 PKCθ (Cell Signaling) and mouse anti E-cadherin primary antibodies.
Speciﬁc binding was detected using an Alexa 488- and Alexa 555-conjugated secondary
antibodies, respectively, so that green staining represents staining for pT538 PKCθ and
red staining represents E-cadherin (in inserts). Nuclei were counterstained using DAPI
(blue). Fluorescent images were collected using a Leica CTR5000 microscope. Panel A
shows acini treated with incubation buffer only (control). Panels B–C show cells treated
for 10 min with 1 μM TPA or 10 nM CCK. Shown are the results of a typical experiment
representative of 4 independent experiments. Cells shown are representative of N90%
of total cells present.
Fig. 7. Ability of CCK and TPA to stimulate the association of PKCθ with Akt, RafA, RafC
and Lyn, in rat pancreatic acinar cells. Panel A: Human recombinant PKCθ protein
solution and pancreatic acinar lysates were immunoprecipitated with anti-C terminal
(Santa Cruz: SC) or N terminal anti-PKCθ antibody (BD Bioscience: BD), or directly
subjected to Western blot (WB alone), and subsequent immunodetected with a
different anti-PKCθ antibody (Cell Signaling: CS). Panel B: Isolated pancreatic acini were
incubated for 2.5 min in the absence and presence of CCK or TPA. Equal amounts of
proteins were immunoprecipitated with an anti-PKCθ (BD) or anti-Lyn antibody, and
then subjected to Western blotting, using as ﬁrst antibody anti-Akt, anti-PKCθ (Cell
Signaling), anti-RafA or anti-RafC antibody. Results are representative of 3 independent
experiments. Panel C: Isolated pancreatic acini were incubated for 2.5 min in the
absence and presence of CCK or JMV. Equal amounts of proteins were immunopreci-
pitated with an anti-PKCθ (BD) or anti-Lyn antibody, and then subjected to Western
blotting, using as ﬁrst antibody anti-PKCθ (Cell Signaling), anti-RafA or anti-RafC
antibody. Results are representative of 3 independent experiments.
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concentrations that caused a maximal PKCθ activation. CCK (10 nM)
(Fig. 7, Panel B, Lane 2) and TPA (1 μM) (Fig. 7, Panel B, Lane 3) produced
an increase in the association of PKCθ with Akt, RafA, RafC and the Src
kinase, Lyn (Fig. 7, Panel B, Rows A–D), but not with MALT-1, Bcl-10,
14-3-3γ or Cbl (data not shown). To ensure that the antibody used for
immunoprecipitation was not the cause of lack of association, we
repeated the Co-IP experiments using the other PKCθ antibody for the
immunoprecipitation and MALT-1, Bcl-10, 14-3-3γ or Cbl antibody forthe immunodetection, and also in the reverse direction: immunopre-
cipitating with MALT-1, Bcl-10, 14-3-3γ or Cbl antibody and immuno-
detection with both PKCθ antibodies, and we did not obtain any
stimulated association with PKCθ by after incubation with CCK or TPA.
In order to establish whether this direct association of PKCθ with
other kinases was produced at low (physiological) or high (supraphy-
siological) CCK concentrations, Co-IP experimentswere performedwith
CCK concentrations that occupy the high or low afﬁnity receptor states
(CCK concentrations: 0.1–1–10 nM) and also with CCK-JMV, known to
be anagonist only of the CCKAhigh afﬁnity state and anantagonist of the
low afﬁnity CCKA receptor state in rat pancreatic acini [18,19]. And we
have found that the direct association of PKCθ with either Lyn, RafA or
RafC was observed also at low CCK concentration and with CCK-JMV
(Fig. 7, Panel C). CCK-JMV stimulated an association of 33±12% of that
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in the T538 PKCθ phosphorylation exerted by JMV in relation to CCK
10 nM (Fig. 3, Panel A).
3.7. Effects of PKCθ inhibition by PKCθ pseudosubstrate on the
phosphorylation of various cellular signaling molecules
In order to investigate further the role of this PKCθ activation in
stimulating various intracellular signaling cascades in pancreatic acini,
we used a PKCθ inhibitor, a PKCθ pseudosubstrate. This is a cell-
permeable myristolyated peptide, and a selective and competitive
inhibitor of this PKC isoenzyme that includes amino acids 113–125 of
the pseudosubstrate sequence. The pseudosubstrate produced an
inhibition of the pT538 phosphorylation of PKCθ stimulated by CCK
(48±3% vs CCK alone pb0.003) or TPA (57±4% vs TPA alone pb0.003)
(Fig. 8, RowA), but it did not affect thephosphorylation of another novel
PKC isoform, PKCδ, known to be present in the pancreas and to be
activated by CCK or TPA [17,48] (Fig. 8, Row B). The possibility of
blocking the activation of PKCθ give us the opportunity to study the
effect of this inhibitor on the activation of kinases known to be
stimulated in pancreatic acini by CCK, such as PKD, Src, RafC, RafA, PYK2,
FAK, IKK, Akt, and p44/42 MAPKs and to assess whether they could be
activated by PKCθ. The inhibition of PKCθ by the PKCθ pseudosubstrate
inhibitor decreased the phosphorylation of PKD stimulated by either
CCK or TPA (Fig. 8, Row C, Lanes 2–3) (19.4±3.69 and 19.1±3.0 folds
over control, respectively, both pb0.05) to values still above the control,
but signiﬁcantly reduced (69±3% and 75±3%, respectively vs
stimulant alone, both pb0.04; Fig. 8, Row C, Lanes 5–6). Similarly,
CCK- and TPA-stimulated Src pY416 phosphorylation was inhibited
(59±3% and 46±6% vs stimulant alone, pb0.02 and pb0.04, respec-
tively; Fig. 8, Row D, Lanes 2–3 and 5–6), RafC (39±6% and 33±64 vs
stimulant alone, pb0.02 and pb0.01, respectively; Fig. 8, Row E, Lanes
2–3 and 5–6). The PKCθ pseudosubstrate partially inhibited CCK or TPA
phosphorylation of pY402 of PYK2 (73±5% and 71±8% vs stimulant
alone, both pb0.05, respectively; Fig. 8 Row F, Lanes 2–3 and 5–6),Fig. 8. Effects of PKCθ inhibition by PKCθ pseudosubstrate in the phosphorylation of PKD,
Src, RafC, PYK2, FAK and IKK. Isolated pancreas acini were preincubated with or without
20 μM PKCθ pseudosubstrate for 3 h and then incubated in the absence or additional
presence of CCK (10 nM) or TPA (1 μM) for 2.5 and 5 min, respectively, and then lysed.
Western blots were analyzed using anti-pT538 PKCθ, anti-pY311 PKCδ, anti-pS744/748
PKD, anti-pY416 Src, anti-pS338 RafC, anti-pY402 PYK2, anti-pY397 FAK, anti-pS180/181
IKKα/β and, as loading control, anti-PKCθ and anti-α/β tubulin antibodies. Results are
representative of 10 independent experiments.pY397 phosphorylation of p125FAK (73±5% and 71±8% vs stimulant
alone, pb0.02 and pb0.01, respectively; Fig. 8, Row G, Lanes 2–3 and
5–6)andpS180/181phosphorylation of IKKα/β (55±6%and56±5%vs
stimulant alone, pb0.04 and pb0.03, respectively; Fig. 8, Row H, Lanes
2–3 and 5–6). However, the increment/decrement in the phosphory-
lation state of other kinases produce by CCK or TPA in pancreatic acinar
cells, such as Akt and p44/42MAPKs, RafA, or p85 PI3Kwas not affected
by the presence of the PKCθ inhibitor, supporting the conclusion that
activation of PKCθ in pancreatic acini is not implicated in the activation
of these enzymes by CCK or TPA.3.8. Effects of PKCθ inhibition by dominant negative PKCθ adenovirus on
the phosphorylation of various cellular signaling molecules
In order to conﬁrm the results obtained with the PKCθ pseudosub-
strate inhibitor, we used another approach, inhibition by a dominant
negativePKCθ adenovirus. This virus contains in its genomea copyof the
PKCθ DNA human sequence with a K/R point mutation at the ATP
binding site which renders it inactive. The infection of pancreatic acini
with this adenovirus produces over-expression of the mutated PKCθ,
where it can function as a dominant negative. Isolated pancreatic acini
were infected for 6 h in the absence or presence of 109pfu/mg [18]
empty adenovirus (control of infection) or the dominant negative PKCθ
adenovirus, and then incubated in the absence or additional presence
of CCK and TPA. After the 6 hour incubation, an overexpression in
PKCθ could be observed (Fig. 9, Panel A, RowA).Moreover, in no case didFig. 9. Effects of PKCθ inhibition by dominant negative PKCθ adenovirus in the
phosphorylation of PKD, Src, RafC, PYK2 and FAK. Isolated pancreas acini were cultured
as described in Materials and methods and infected without and with an empty
adenovirus or a dominant negative PKCθ adenovirus for 6 h, incubated in the absence or
additional presence of CCK (10 nM) or TPA (1 μM) for 2.5 and 5 min, respectively, and
then lysed. Western blots were analyzed using: Panel A: anti-PKCθ, anti-pT538 PKCθ,
anti-pY311 PKCδ and, as loading control, anti-α/β tubulin antibodies; Panel B: anti-
pS744/748 PKD, anti-pY416 Src, anti-pS338 RafC, anti-pY402 PYK2, anti-pY397 FAK
and, as loading control, anti-α/β tubulin antibodies. Results are representative of 4
independent experiments.
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expression or result in a change in the ability by CCK or TPA to stimulate
pT538 phosphorylation of PKCθ itself (Fig. 9, Panels A and B, Rows A–F,
Lanes 4–6). These results supported the conclusion that if any change in
the phosphorylation of the enzymewas observed it would be due to the
dominant negative PKCθ, and not because of the adenovirus infection.
Over-expression of the dominant negative PKCθ did not alter the
increment in the PKCδ phosphorylation induced by CCK or TPA (Fig. 9,
Panel A, Row C), but it produced a completely inhibition of the pT538
PKCθ phosphorylation (Fig. 9, Panel A, Row B), showing that the
inhibition of the PKCθ dominant negative adenoviruses is speciﬁc and it
is not affecting the activation of another novel PKC isoform, PKCδ, which
is known to be expressed and activated by CCK in the pancreatic acini
[17,48].
The over-expression of the dominant negative PKCθ produced a
marked decrease in the stimulation caused by CCK or TPA in the
phosphorylation of PKD, Src, RafC, PYK2 and FAK (Fig. 9, Panel B, Rows
A–E, Lanes 1–3 vs 7–9), similar to what was observed when cells were
preincubated in the presence of the PKCθ pseudosubstrate inhibitor
(Fig. 8).
3.9. Effects of PKCθ inhibition in amylase release
In order to study the possible implication of PKCθ activation in the
stimulation of amylase release in rat acinar cells, isolated acini were
preincubated in the presence of 20 μM PKCθ pseudosubstrate
inhibitor and subsequently incubated with different stimulants
(Table 2). The preincubation with the PKCθ inhibitor did not produce
any modiﬁcation in the stimulation in the amylase secretion by CCK,
carbachol or VIP, all known stimulants of pancreatic acinar cells
secretion (Table 2).
4. Discussion
The purpose of the present study was to determine whether
gastrointestinal hormones/neurotransmitters can activate the novel
protein kinase, PKCθ, and if so, to provide insights into the possible
mechanisms of its interactions with various known important cellular
mediators of the actions of these GI stimulants. This was performed
studying pancreatic acinar cells after ﬁrst determining whether
PKCθ is present in the cells. Particular attention was paid to the
hormone/neurotransmitter, cholecystokinin (CCK), because it is not
only a physiological regulator of pancreatic acinar cell function, it is
also important in a number of important pathological processes
affecting acinar cell function, such as pancreatitis [23,25,26].
The ability of GI hormones/neurotransmitters and GI growth factors
to activate PKCθ was investigated using pancreatic acinar cells for a
number of reasons. First, pancreatic acini are known to be highly
responsive and activated by numerous GI hormones/neurotransmittersTable 2
Effect of PKCθ inhibition on amylase secretion.
Secretagogue Amylase secretion (% total)
−PKCθ inhibitor +PKCθ inhibitor
None 1.7±0.2 1.7±0.2
CCK (0.03 nM) 5.1±0.8 5.8±0.9
(0.1 nM) 7.1±0.6 7.4±0.6
(100 nM) 4.5±0.4 4.5±0.3
Carbachol (1 μM) 6.8±0.7 7.0±0.5
(1 mM) 6.2±0.7 6.3±0.6
VIP (10 nM) 3.4±0.6 3.6±0.4
Pancreatic acini were pre-incubated for 2 h with 20 μM PKCθ pseudosubstrate and then
for 15 min with the indicated secretagogues. Amylase secretion is expressed as the
percentage of the total acinar cell amylase released into the medium during the
incubation. Results are means±S.E. from 6 different experiments.and growth factors, and this cell systemhas beenwidely used as amodel
system to study the cellular signaling and effects of these stimulants
[14–17]. Second, there is very little information on the ability of
gastrointestinal hormones/neurotransmitters or growth factors to
activate this novel PKC. Third, previous studies have demonstrated
activation of other novel PKCs (PKCδ, ε), aswell as the conventional PKC,
PKCα, are important in mediating some of CCK's physiological and
pathophysiological effects in the pancreas, aswell as the effects on these
cells by a number of other gastrointestinal hormones/neurotransmitters
and growth factors [14,20,21,24,48,49].
A number of our results support the conclusion that PKCθ is present
in pancreatic acinar cells, even thoughprevious studies havepresented
conﬂicting results. In a recent review of PKCs in pancreatic acinar cells,
as well as in four different studies [20,50–52], only four of the 12
known PKCs isoformswere reported to be present in pancreatic acinar
cells and PKCθ was not one of them (PKCα, δ, ε and ζ). However, in
other studies the presence of PKCθ has been found in two pancreatic
acinar tumor cell lines (TUC3 and BMRPA.430) [29,32], reported to be
present weakly in one study using immunoblotting in isolated rat
pancreatic acinar cell lysates [32] and to be present in acinar cells from
human pancreas in 15% of the cases studied [31], as well as to be
present in guinea pig pancreatic duct cells [53] and pancreatic islet rat
β-cells [11]. We established that PKCθ was present in rat pancreatic
acini using three different approaches. First, we established that PKCθ
was present using immunoblotting and detection with antibodies
speciﬁc for PKCθ, which under the experimental conditions used in the
present study, did not cross-react with other PKCs, including novel
PKCs (δ, ε) known to be present in acinar cells [20,50–52]. The
speciﬁcity of the results for pancreatic acinar cells was established by
preparing dispersed isolated rat pancreatic acini and detecting PKCθ in
these cells and comparing the result with known PKC standards
assessed under identical assay conditions, which established the
speciﬁcity of the antibodies used for the detection of PKCθ. Second, we
detected the presence of PKCθmRNA by PCR using primers speciﬁc for
PKCθmRNA and demonstrated that the PCR product was similar with
that found in two other tissues known to contain the PKCθ isoform,
muscle and brain. Third, we demonstrated by immunoﬂuorescence
using a speciﬁc PKCθ antibody, the presence of PKCθ in isolated rat
pancreatic acini in the cytoplasm and its subsequent translocation to
the acinar cell membrane after the acini were exposed to a known
physiological stimulant of pancreatic acinar function, CCK [25].
In this study we next assessed the ability of various GI hormones/
neurotransmitters, as well as GI growth factors to activate PKCθ. A
number of our results support the conclusion that pancreatic
stimulants that interact with G-protein-coupled receptors in acinar
cells and stimulate phospholipase C (PLC)-mediated pathways, but not
other cascades, nor pancreatic growth factors, activate PKCθ. First, only
carbachol, bombesin and CCK, all known to activate the PLC-cascade in
pancreatic acinar cells [15], and not GI hormones/neurotransmitters
which activate adenylate cyclase (VIP or secretin) or stimulate
directly PKA (8-Br-cAMP) [15] stimulated T538 PKCθ phosphoryla-
tion. Second, none of the known pancreatic growth factors (insulin,
EGF, PDGF, VEGF, bFGF, IGF and HGF) stimulated T538 PKCθ
phosphorylation. This lack of activation by growth factors was not
due to their inability to stimulate pancreatic acinar cells because
previous studies show that speciﬁc receptors for these growth
factors exist on these cells and their activation stimulates a number
of cellular signaling cascades [15,19]. Moreover, we demonstrated that
the increase activation of PKCθ by CCK is due to the activation of
CCKA receptor only, andnot due to thebindingof CCK to apossibleCCKB/
gastrin receptor that could be present in the rat pancreatic acinar cell or
other accompanying cells. Although in other species, CCKB receptors are
present in pancreatic acinar cells and they are present in the rat
pancreatic acinar cell line, AR42J cells, or results are consistent with
other studies which demonstrate only CCKA receptors on rat pancreatic
acini [15,40,54].
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different approaches, ﬁrst stimulation of T538 PKCθ phosphorylation,
second stimulation of PKCθ translocation, and third measurement of
stimulation of PKCθ kinase activity. T538 PKCθ phosphorylation was
assessed because previous studies showed that PKCθ is phosphory-
lated in 3 different sites (T538, S695 and S676), with its activation of
kinase catalytic activity [1,2]. The phosphorylation of the T538 site
plays an essential role in PKCθ activation, becausemutation of this site
leads to a PKCθ that does not undergo activation or translocation with
known stimulants [33]. Furthermore, there is a close correlation
between the PKCθ T538 phosphorylation state and its kinase catalytic
activity [47]. For that reason, increments in phosphorylation of T538
PKCθ have been widely used to assess PKCθ activation in a number of
tissues including, not only in T cells or T cell lines [10,47], but also in a
number of other cells [13]. Thirdly, we also demonstrated PKCθ's
activation by demonstrating its translocation to membranes when
stimulated by some of these agents. Once phosphorylated by its
activators, PKC isoforms translocate to the membrane where they can
phosphorylate various protein/substrates. In fact, after stimulation PKCθ
has been shown to translocate tomembranes in T cells [55],muscle cells
[56] andmast cells [7].We demonstrate that in rat pancreatic acinar cell
with stimulation by CCK there is an increase membrane-associated
PKCθ. These results were established through two different approaches,
ﬁrst using Western blotting and immunodetection of PKCθ with
speciﬁc PKCθ antibodies in fractionatedmembranes from rat pancreatic
acinar cell and demonstrating an increase of PKCθ in membranes after
incubation with CCK or TPA (PKC activator); and second, using
immunoﬂuorescence in isolated rat pancreatic acinar cells with speciﬁc
PKCθ antibodies, treatment with CCK or TPA resulted in the accumu-
lation of phospho-T538 PKCθ in themembrane. These results have some
similarities anddifferences fromprevious studies of the ability of various
agents to activate PKCθ in other tissues. They are similar in that a number
of other GI hormones/neurotransmitters in other systems can also
activate PKCθ. Speciﬁcally, muscarinic cholinergic agents activate PKCθ
in muscle [57] and bombesin-related peptides in human antral G cells
[58]. There are no studies reporting the ability of agents that activate
adenylate cyclase/PKA to stimulate PKCθ. However, our results with
activation of PKCθ differ from studies with other novel PKC isoforms in
other tissues, which demonstrate both dBcAMP/8-Br-cAMP/CPT-cAMP
or agents that activate adenylate cyclase, can stimulate their activation.
Speciﬁcally, synthetic cAMP analogs activate PKCδ in hepatocytes [59]
and VIP activates PKCδ in cortical astrocytes [60]. Our results with
growth factors differ from studies reporting that insulin is able to
increase PKCθ activation in myocytes [56], EGF increases T538 PKCθ
phosphorylation in A431 cells [61] and that IGF-1 increases PKCθ
catalytic activity in rhabdomyosarcoma cell line [62]. These results
demonstrate that a selected group of GI hormones/neurotransmitters
that activate the PLC cascade can activate PKCθ in pancreatic acinar cells.
However, our resultswith growth factors differ from the results reported
in some other tissues suggesting that PKCθ responsiveness may be
tissue-speciﬁc. Furthermore, the lack of response to cAMP/PKA agents in
pancreatic acinar cells, suggests PKCθ responsiveness to this signaling
cascade, differs from that reported for theGI hormone/neurotransmitter
VIP, as well as for other stimulants, for other novel isoform of PKCs in
other tissues, suggesting that the PKCθ responsiveness to the agentsmay
also be tissue speciﬁc or novel PKC subtype speciﬁc.
Numerous studies support the conclusion that in pancreatic acinar
cells, the CCKA receptor exists in two different states, a high afﬁnity
and low afﬁnity state, each of which activates different signaling
cascades [15,26,63]. In the present study CCK's stimulation of T538
PKCθ phosphorylation was detectable at 0.1 nM, with a half-maximal
effect at 0.174 nM and a maximal effect at 10 nM in pancreatic acinar
cells. These results have both similarities and differences from the
ability of CCK to stimulate other novel PKC kinases in pancreatic acinar
cells. Speciﬁcally, CCK-stimulated maximal PKCmu (PKD1) activation
at a similar concentration to that observed for PKCθ (10 nM), however10-fold higher CCK concentrations were required to fully activate
PKCδ (100 nM). These results demonstrate that different novel PKCs
in pancreatic acinar cells have different dose–response curves for CCK
activation. Several results from this study support the conclusion that
full activation of PKCθ by CCK in pancreatic acini requires activation of
both, the high and low, CCKA afﬁnity receptor states. Activation of
PKCθ in pancreatic acinar cells by CCK occurs over a 5-log-fold range
of CCK concentrations, with PKCθ stimulation occurring with CCK
concentrations which has been shown in other studies to activate
both the high and low afﬁnity CCKA receptor states [15,38]. This
conclusion is supported by the results with the synthetic analog, CCK-
JMV, which, in rat pancreatic acinar cells, functions as an agonist of the
high afﬁnity CCK receptor state and an antagonist of the low afﬁnity
receptor state [15,38,39]. CCK-JMV produced 30% of themaximal PKCθ
activation exerted by CCK. As CCK-JMV is an agonist of only the high
afﬁnity CCKA receptor state [39], these results with CCK-JMV demon-
strate that CCK causes 30% of its maximal PKCθ activation through
activation of the high afﬁnity CCKA receptor state and the remaining70%
of maximal activation is due to activation of low afﬁnity CCKA receptor
state. These results show similarities and differences from CCKA
receptor-mediated phosphorylation of other kinases or proteins in
pancreatic acinar cells. PKCθ activation by CCK is similar to CCK-
mediated activation of the Src kinase, Lyn [64], PYK2/CAKβ [17], p125FAK
[27], paxillin [16] and the novel PKC, PKCmu (PKD1) [18] in pancreatic
acinar cells, in that in each case, maximal activation requires CCKAR
activation of both the high and low states. However, these different
signaling cascades differ in the relative importance of the high afﬁnity
and low afﬁnity CCK receptor states. Activation of the high afﬁnity CCKA
receptor state is responsible for only 20% of the maximal activation of
PKCmu (PKD1) [18] and PYK2/CAKβ [17], whereas it mediates 50% of
the maximal stimulation of p125FAK and paxillin phosphorylation [65]
and mediates 60% of Lyn activation [64]. These results with PKCθ
activation differ from the results seen with CCK activation in pancreatic
acinar cells of the novel PKC, PKCδ [14] or stimulation of phosphory-
lation of the adaptor protein, CrKII, [66] where they are mediated only
through activation of the low afﬁnity CCKA receptor state. In contrast,
CCK-mediated activation of PI-3 kinase and phospholipase D in
pancreatic acinar cells is mediated entirely by the activation of the
high afﬁnity receptor state [67]. These results demonstrate that not only
do the CCKA receptor states differ in their coupling to pancreatic cellular
kinase cascades, but evenwith different novel PKCs in the same cell, the
CCKAR receptor activation states show differential coupling.
In other cells activated by various stimulants, PKCθ activation is
known to be important in the stimulation of a number of important
cellular signaling proteins [5], including Src, [41], PKD [42], Raf [42,68],
CARMA and IKK/NFκβ [43], Cbl [44,47], 14-3-3 [45], Blc-10 [46],MALT-1
[47], PI3K [19], ERK [13], IRS-1 [12], p125FAK [69] and Akt [12]. In
pancreatic acinar cells, stimulation by growth factors and GPCRs causes
activation of a number of these cellular signaling proteins, including Src
kinases [64], PKD [18,49], Raf [70], IKKα/β/NFκβ [49], PI3K [19,71],
p44/42 MAPKs [72], p125FAK, PYK2 and paxillin and Akt [19], which
have been shown to be important in mediating cell activation, enzyme
secretion [73,74], proliferation and apoptosis [19], cell survival [75] and
protein synthesis [76]. Furthermore, activation of a number of these
signaling pathways such as NFκβ plays a critical role in pathological
processes such as inﬂammatory and cell death responses of pancreatic
acinar cells in acute pancreatitis [21,49,72]. A number of our results
support the conclusion that PKCθ activation by CCK or TPA plays an
important role in the activation of a number of these cellular signaling
cascades inpancreatic acinar cells. First, usinga speciﬁc pseudosubstrate
PKCθ inhibitor [22] we observed a decrease in the CCK- and TPA-
stimulated phosphorylation/activation of PKD1 (PKCmu), Src, RafC,
PYK2, p125FAK and IKKα/β, but no effect on phosphorylation/activation
of AKT or p44/42 MAPKs. Second, with speciﬁc inhibition of the PKCθ
activation by the overexpression, in isolated pancreatic acinar cells, of a
PKCθ dominant negative form by adenovirus infection, we found also a
2155V. Sancho et al. / Biochimica et Biophysica Acta 1813 (2011) 2145–2156decrease in the CCK- and TPA-stimulated phosphorylation/activation of
PKD1 (PKCmu), Src, RafC, PYK2, FAK and IKKα/β, but no effect onAKTor
p44/42 MAPKs phosphorylation/activation. That these results were
speciﬁc for PKCθ were supported by the ﬁndings that neither the
pseudosubstrate PKCθ inhibitor nor the dominant negative PKCθ,
altered the activity of PKCδ, another novel PKC expressed in acinar
cells [14]. These results show similarities and some important
differences from results with PKCθ activation reported in other studies
in other tissues. They are similar to results with PKD activation in COS-7
and Jurkat cells,whichwasdependent onPKCθ activation [42] and in the
case of activation of the IKKα/β-NFκβ pathway in T cells by CD3/CD28,
which is also dependent on PKCθ activation [5]. They differ in that we
found no alteration by the inhibition of PKCθ activation in the
phosphorylation/activation of AKT or p44/42 MAPK with pancreatic
acinar cells stimulated by either CCK or TPA, which are well-established
stimulants in pancreatic acini of both AKT [19] and p44/42 MAPK [77].
Previous studies have provided evidence that other two novel PKCs
(PKCδ, PKCε) found in pancreatic acinar cells, are activated by CCK and
TPA [14,20,21,48], and their activation is important for a number of
physiological and pathological responses of the acinar cell [49]. Our
results support the conclusion that PKCθ is also involved in the
activation of many of these cellular signaling cascades involved in
several of these effects in pancreatic acinar cells, and in future studies,
which of the three novel kinases is most important in producing these
various cell effects will need to be investigated.
Our results not only provide evidence for the participation of PKCθ in
the activation of other kinases in pancreatic acinar cells, but also support
the conclusion that it can affect various signaling cascades by a direct
association of this novel PKC isoform, observed not only at high but also
at low doses, with different protein/kinases implicated in various
cellular signaling cascades. This conclusion is supported by the results of
our co-immunoprecipitation experiments,which showed that both CCK
and TPA stimulated the association of PKCθ with the Src kinase, Lyn;
AKT; RafA and RafC, but not an association with p85 PI3K, PKD1, RafB,
Bcl-10, Cbl, MALT-1, tubulin or 14-3-3 protein. These results have
similarities and differences with other studies in other tissues. They are
similar in the case of the direct association of PKCθwith amember of the
Src kinase family, because in Jurkat, RBL-2H3 and T cells co-stimulation
by CD3/CD28, produces an increase in the direct association of PKCθ
with Src kinases (Src, Lyn, Lck and Fyn) [41,46,55]; and in the case of Raf
proteins in Cos-1 transfected cells with PKCθ and Raf proteins, upon
stimulation with TPA, a direct association of PKCθ with RafC and RafB
occurred [68]. Our results show also differences with other studies in
other tissues,which reported a direct association of PKCθwith PI3K, Cbl,
Bcl-10, MALT-1, tubulin and 14-3-3 protein [44,45,47]. They also differ
from other studies in that for the ﬁrst timewe ﬁnd that with pancreatic
acinar cells activation of PKCθ stimulated a direct associate with AKT,
which has been shown to be important in mediating pancreatic
processes including enzyme secretion or apoptosis and in pathological
processes, such as pancreatitis and pancreatic cancer growth [19,78].
The role of other PKC novel isoforms in amylase release in rat
pancreatic acinar cells is controversial with one study [79] concluding
that PKCδ is not implicated in this secretory effect of CCK or carbachol in
acinar cells from guinea pigs or PKCδ−/− rats. Another study [20],
though, proposed that the PKCδ isoform, and not the PKCε, is important
in mediating amylase release. Our results support the conclusion that,
PKCθ, is not implicated in the amylase secretion produced by CCK,
carbachol or VIP, as its inhibition did not alter the amylase release
evoked by secretagogues either activating phospholipase C or adenylate
cyclase.Acknowledgements
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